NMDB.F Stock Overview
NeonMind Biosciences Inc. engages in the drug development of psychedelic compounds in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NeonMind Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.23 |
| 52 Week High | CA$6.73 |
| 52 Week Low | CA$0.12 |
| Beta | -1.17 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -95.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| NMDB.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -0.2% |
| 1Y | -95.8% | 17.9% | 28.2% |
Return vs Industry: NMDB.F underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: NMDB.F underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| NMDB.F volatility | |
|---|---|
| NMDB.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NMDB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NMDB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Rob Tessarolo | www.neonmindbiosciences.com |
NeonMind Biosciences Inc. operates as an integrated psychedelic drug development and wellness company in Canada. The company provides psychedelic drugs to address public health needs, including obesity, weight management, and mental health. It operates in two divisions, Pharmaceutical and Medical Services.
NeonMind Biosciences Inc. Fundamentals Summary
| NMDB.F fundamental statistics | |
|---|---|
| Market cap | US$245.73k |
| Earnings (TTM) | -US$1.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NMDB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMDB.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.45m |
| Earnings | -CA$2.45m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -61.2% |
How did NMDB.F perform over the long term?
See historical performance and comparison